Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

NCT05411497 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

BIOLOGICAL: Autologous MUC1-activated T-cells
DRUG: Cyclophosphamide

Sponsor

Mayo Clinic